Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
Meric-Bernstam F, Yuca E, Evans KW, Zhao M, Maejima T, Karibe T, Raso MG, Tang X, Zheng X, Rizvi YQ, Akcakanat A, Scott SS, Wang B, Byers LA, Tripathy D, Okajima D, Damodaran S.
Meric-Bernstam F, et al. Among authors: scott ss.
Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-1948. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39585341